Cardinal Health Inc. (NYSE: CAH) provides healthcare services, pharmaceuticals, and medical products to institutions and individuals globally. Cardinal Health was founded in 1971 and has been listed on the NYSE since 1983. Cardinal Health generated USD 205 billion in revenue in FY2023 (year ending on June 30).
Cardinal Health’s Pharmaceutical segment (~93% of total revenue in FY2023) offers branded and generic pharmaceuticals, specialty pharmaceuticals, and over-the-counter healthcare and consumer products. The Medical segment (~7%) manufactures, sources, and distributes a range of medical, surgical, and laboratory products under its own brand.
The US was Cardinal Health’s primary market (~98% of total revenue in FY2023). The company targets Pharmaceutical segment revenue growth of ~10% (14.8% in FY2023) and Medical segment revenue growth of 3% to 4% over FY2024–FY2026 (-5.5% in FY2023). Cardinal Health is also committed to achieving a 50% reduction in Scope 1 and Scope 2 emissions by FY2030 (from a FY2019 baseline).
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.